NCT05499780View on ClinicalTrials.gov

Study on Performance and Safety of Sentinox in the Prevention of Acute Respiratory Infections (ARI)

NATerminatedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

November 7, 2022

Primary Completion Date

February 27, 2023

Study Completion Date

September 13, 2023

Conditions
Healthy Volunteers
Interventions
DEVICE

Sentinox

The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.

Trial Locations (1)

16132

Ospedale Policlinico San Martino IRCCS, Genova

Sponsors
All Listed Sponsors
lead

APR Applied Pharma Research s.a.

OTHER